TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development

Stefan H.E. Kaufmann, Hazel M. Dockrell, Nick Drager, Mei Mei Ho, Helen McShane, Olivier Neyrolles, Tom Ottenhoff, Brij Patel, Danielle Roordink, François Spertini, Steffen Stenger, Jelle Thole, Frank A.W. Verreck, Ann Williams, Warwick Britton, Jamie Triccas, Claudio Counoupas, Johan Grooten, Demoitie Marie-Ange Demoitie, Marta RomanoKris Huygen, Hermann Giresse Tima, Francoise Mascart, Peter Andersen, Claus Aagaard, Dennis Christensen, Morten Ruhwald, Thomas Lindenstrom, Pierre Charneau, Christophe Guilhot, Antonio Peixoto, Martine Gilleron, Isabelle Vergne, Camille Locht, Roland Brosch, Genevieve Inchauspe, Stephane Leung Theung Long, January Weiner, Jeroen Maertzdorf, Natalie Nieuwenhuizen, Max Bastian, Stephanie Kallert, Stephen Gordon, Nadia Caccamo, Delia Goletti, Roberto Nisini, Sung Jae Shin, Sang Nae Cho, Hyejon Lee, Ino Choi, TBVAC2020 Consortium

Research output: Contribution to journalReview articlepeer-review


TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Original languageEnglish
Article number1203
JournalFrontiers in Immunology
Issue numberOCT
Publication statusPublished - Oct 4 2017


  • Bacille Calmette-Guérin
  • Biomarker
  • Clinical trial
  • Discovery
  • Portfolio management
  • Tuberculosis
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development'. Together they form a unique fingerprint.

Cite this